BioMarin Pharmaceuticals (BMRN) traded lower on April 10, 2026, with the decline tied to lingering fallout from its latest earnings update and forward-year guidance. The key pressure point is profitability expectations: BioMarin’s guided 2026 non-GAAP diluted EPS range of $4.95–$5.15 came in below the consensus EPS figure cited in the market recap, even as revenue guidance roughly bracketed consensus.

In the most recent quarterly report, BioMarin posted Q4 EPS of $0.46 versus an analyst estimate of $0.77, while revenue was $875 million versus an estimate of about $829 million. For 2026, BioMarin guided revenue of $3.33–$3.43 billion and reiterated a profitability framework that implies investors will need to see cleaner margin expansion to support a higher multiple.

BioMarin has also been managing portfolio noise around ROCTAVIAN after deciding to voluntarily withdraw the therapy from the market, which it said drove roughly $240 million of charges in Q4 (including an inventory write-off and long-lived asset impairments). With the stock already sensitive to VOXZOGO trajectory and longer-dated pipeline catalysts, any uncertainty around near-term earnings power can translate quickly into downside volatility.

The pending all-cash acquisition of Amicus Therapeutics is another focal point for investors, given the added leverage and integration costs implied in BioMarin’s 2026 guidance framework. BioMarin has already lined up significant financing, including a private offering of $850 million senior unsecured notes due 2034 intended to help fund the acquisition, with closing targeted for Q2 2026 subject to customary conditions.